Irritable bowel syndrome trials in Germany

In Germany 6 Also abroad 159

6 of 6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
Where
Bamberg
Age
18 years to 75 years
People
118
Run by
Universität Duisburg-Essen
See details and how to joinNCT06145022
Phase 2Taking people
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Where
Berlin, Dachau, Hamburg, Karlsruhe, Leipzig, Offenbach
Age
18 years to 75 years
People
531 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07545759 · EU 2025-524973-17-00
Phase 4Taking people
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)
Where
Berlin, Frankfurt am Main, Goch, Hamburg, Hannover, Jerichow, Karlsruhe, Schwerin
Age
18 years and over
People
268
Run by
REPHA GmbH Biologische Arzneimittel
See details and how to join2024-514892-16-00
Phase 4Taking people
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D)
Where
Bamberg, Berlin, Bochum, Frankfurt am Main, Hanover, Karlsruhe, Leipzig, Reinfeld
Age
18 years and over
People
220
Run by
REPHA GmbH Biologische Arzneimittel
See details and how to join2024-514383-61-00
Phase 4Not yet taking people in Germany
Amara-Tropfen vs. placebo for irritable bowel syndrome (IBS)
Where
Böhlen, Essen, Frankfurt, Goch, Hamburg, Jerichow, Münster, Wallerfing
Age
18 years and over
People
106
Run by
Weleda AG
See details and how to join2026-526668-19-00
Phase 4Taking people
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)
Where
Ahrensburg, Bamberg, Berlin, Böhlen, Brandenburg an der Havel, Dresden, Essen, Frankfurt Am Main, Fulda, Gera, Gladbeck, Goch, Hamburg, Hanover, Heidelberg, Jerichow, Karlsruhe, Köthen, Leipzig, Naunhof, Nürnberg, Offenbach, Reinfeld, Schwerin, Stuttgart, Wiesbaden
Age
18 years and over
People
422
Run by
SymbioPharm GmbH
See details and how to join2024-512104-19-00